12:00 AM
 | 
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ethyol amifostine: Phase III data; marketed

UBS presented previously reported data from a 315-patient Phase III trial showing that 51 percent of Ethyol-treated patients experienced post-operative grade 2 xerostomia compared to 78 percent of...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >